Apollo Health Ventures
Transatlantic early-stage venture capital firm that co-founds and invests in biotechnology and health-technology companies targeting aging and age-related diseases. Uses a combination of venture building (Venture Lab) and external early-stage investments to develop therapeutics, data platforms and health tech with the objective of impacting human health within the next decade.
Services
Venture creation / Venture Lab
Co-founding startups with scientific experts and research institutes to turn untapped technologies into companies; acquiring founder shares at nominal value through active company formation and operational support.
Equity funding (seed to early growth)
Investment in Seed and Series A rounds (including late-seed and occasionally Series B) for biotech, data platforms and health tech companies targeting age-related diseases and aging.
Syndicate & capital access
Introducing portfolio companies to follow-on investors and leading players for subsequent rounds, leveraging an extensive network in Europe and the US.
Scientific, R&D and clinical development guidance
Support in R&D strategy, clinical trial design, indication selection and scientific de-risking through internal expertise and external advisors.
Talent and leadership recruitment
Support for hiring senior leadership and building teams for portfolio companies through in-house recruiters and networked hiring resources.
Operational support and risk-reduction experiments
Operational assistance including designing and running 'killer' experiments to de-risk early-stage science and minimize technical risk before heavy capital deployment.
Venture creation / Venture Lab
Co-founding startups with scientific experts and research institutes to turn untapped technologies into companies; acquiring founder shares at nominal value through active company formation and operational support.
Equity funding (seed to early growth)
Investment in Seed and Series A rounds (including late-seed and occasionally Series B) for biotech, data platforms and health tech companies targeting age-related diseases and aging.
Syndicate & capital access
Introducing portfolio companies to follow-on investors and leading players for subsequent rounds, leveraging an extensive network in Europe and the US.
Scientific, R&D and clinical development guidance
Support in R&D strategy, clinical trial design, indication selection and scientific de-risking through internal expertise and external advisors.
Talent and leadership recruitment
Support for hiring senior leadership and building teams for portfolio companies through in-house recruiters and networked hiring resources.
Operational support and risk-reduction experiments
Operational assistance including designing and running 'killer' experiments to de-risk early-stage science and minimize technical risk before heavy capital deployment.
Portfolio
Closed a $50M follow-on round and is moving towards human clinical trials (news March 2024).
#Pharmaceuticals / therapeutics
Secured Series A financing ($48M in 2022), FDA clearances, Fast Track designation and a $27M Series B (2025); developing an AI-powered multi-omics platform (AURIGIN™).
#Precision oncology / targeted cancer therapeutics
Published positive topline data from a Phase 1 clinical trial for BL-001 (Dravet syndrome and ALS).
#Therapeutics (neurology)
Launched with $15M seed financing led by Apollo Health Ventures and Novo Holdings (Oct 2024).
#Therapeutics (proteasome activator medicines)
Raised $2.5M seed financing to advance FOXO4-therapeutics for cancer and chronic diseases (Sept 2022).
#Biotech / therapeutics
Launched as a new cellular reprogramming startup in partnership with Paul Scherrer Institute (Oct 2022).
#Cellular reprogramming / regenerative biotech
Closed a $50M follow-on round and is moving towards human clinical trials (news March 2024).
#Pharmaceuticals / therapeutics
Secured Series A financing ($48M in 2022), FDA clearances, Fast Track designation and a $27M Series B (2025); developing an AI-powered multi-omics platform (AURIGIN™).
#Precision oncology / targeted cancer therapeutics
Published positive topline data from a Phase 1 clinical trial for BL-001 (Dravet syndrome and ALS).
#Therapeutics (neurology)
Launched with $15M seed financing led by Apollo Health Ventures and Novo Holdings (Oct 2024).
#Therapeutics (proteasome activator medicines)
Raised $2.5M seed financing to advance FOXO4-therapeutics for cancer and chronic diseases (Sept 2022).
#Biotech / therapeutics
Launched as a new cellular reprogramming startup in partnership with Paul Scherrer Institute (Oct 2022).
#Cellular reprogramming / regenerative biotech